SERAGEN, INC. HAS OMITTED FROM THIS EXHIBIT 10.56 PORTIONS OF THE AGREEMENT FOR WHICH SERAGEN, INC. HAS REQUESTED CONFIDENTIAL TREATMENT FROM THE SECURITIES AND EXCHANGE COMMISSION. THE PORTIONS OF THE AGREEMENT FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED ARE INDICATED "[ ]" AND SUCH CONFIDENTIAL PORTIONS HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
AMENDMENT TO SALES AND DISTRIBUTION AGREEMENT
This Amendment is entered into effective as of the 28th day of May, 1996 by and between Eli Lilly and Company, an Indiana corporation ("Lilly"), and Seragen, Inc., a
Delaware corporation ("Seragen").
RECITALS
A. Lilly and Seragen are parties to a Sales and Distribution Agreement dated as of August 3, 1994 (as amended to date, the "Distribution Agreement").
B. Pursuant to the Distribution Agreement, Lilly has paid to Seragen five million dollars ($5,000,000), which, in accordance with the Distribution Agreement is to be repaid to Lilly via a credit against Bulk Sales Price due Seragen by Lilly under the Distribution Agreement.
C. Lilly and Seragen desire to amend the Distribution Agreement in certain respects relating to Seragen's obligation to repay this five million dollar ($5,000,000) advance.
AGREEMENT
The parties for good and valuable ...